Research location
Wilrijk
Belgium
Advertisement
Research activity in Wilrijk
BelgiumCureCurrent currently publishes aggregate city-level research activity for this location: 178 trials and 178 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Wilrijk
178 linked trials · page 1 of 4RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositiveNCT07413939 · 2026-05-21 · 1 site observation
RECRUITING
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)NCT07531095 · 2026-04-21 · 1 site observation
RECRUITING
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT07164443 · 2025-09-02 · 1 site observation
RECRUITING
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant TumorsNCT07070232 · 2025-08-12 · 1 site observation
RECRUITING
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationNCT06952803 · 2025-08-06 · 1 site observation
RECRUITING
OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)NCT06462963 · 2025-04-15 · 1 site observation
RECRUITING
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.NCT05939414 · 2024-03-12 · 1 site observation
RECRUITING
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast CancerNCT05950945 · 2023-12-30 · 1 site observation
RECRUITING
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31 · 1 site observation
RECRUITING
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · 2022-12-12 · 1 site observation
RECRUITING
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)NCT04790253 · 2022-10-27 · 1 site observation
RECRUITING
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung CancerNCT06497556 · 2024-09-23 · 1 site observation
ACTIVE_NOT_RECRUITING
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast CancerNCT06328738 · 2024-05-30 · 1 site observation
ACTIVE_NOT_RECRUITING
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast CancerNCT06239467 · 2024-02-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)NCT06065748 · 2023-12-11 · 1 site observation
ACTIVE_NOT_RECRUITING
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)NCT05952557 · 2023-10-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)NCT05629585 · 2022-11-28 · 1 site observation
ACTIVE_NOT_RECRUITING
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerNCT05565378 · 2022-10-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)NCT05374512 · 2022-05-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Evaluation of Glycemic Control in Adults With Type 1 Diabetes When Switching to Insulin DegludecNCT05434559 · 2022-02-20 · 1 site observation
COMPLETED
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesNCT05081609 · 2022-01-11 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)NCT04961996 · 2021-08-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Olive Polyphenols in Cardiovascular PreventionNCT04874961 · 2021-05-20 · 1 site observation
COMPLETED
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)NCT04622319 · 2020-12-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate CancerNCT04577833 · 2020-11-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast CancerNCT04305496 · 2020-04-16 · 1 site observation
ACTIVE_NOT_RECRUITING
The Impact of Hybrid Closed-loop Insulin Delivery in Type 1 Diabetes on Glycemic Control and PROMsNCT04414280 · 2020-03-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate CancerNCT04100018 · 2020-02-06 · 1 site observation
COMPLETED
Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:NCT03875573 · 2019-11-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RPNCT03899077 · 2019-04-05 · 1 site observation
UNKNOWN
IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II StudyNCT03705403 · 2019-04-04 · 1 site observation
TERMINATED
Comparing Continuous With Flash Glucose Monitoring in Adults With Type 1 DiabetesNCT03772600 · 2019-01-29 · 1 site observation
COMPLETED
Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBCNCT03616886 · 2018-12-28 · 1 site observation
ACTIVE_NOT_RECRUITING
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerNCT03701334 · 2018-12-07 · 1 site observation
ACTIVE_NOT_RECRUITING
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial CancerNCT03523572 · 2018-08-02 · 1 site observation
COMPLETED
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.NCT03330847 · 2018-03-07 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic TumorsNCT03289962 · 2017-12-21 · 1 site observation
COMPLETED
Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)NCT03361865 · 2017-12-04 · 1 site observation
COMPLETED
Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate CancerNCT02799706 · 2017-09-25 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast CancerNCT03197935 · 2017-07-24 · 1 site observation
COMPLETED
A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human BrainNCT03089918 · 2017-05-17 · 1 site observation
COMPLETED
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid TumorsNCT02983045 · 2016-12-19 · 1 site observation
COMPLETED
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCNCT02941926 · 2016-11-30 · 1 site observation
COMPLETED
An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair AnomaliesNCT02854436 · 2016-08-31 · 1 site observation
COMPLETED
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)NCT02900664 · 2016-08-23 · 1 site observation
COMPLETED
Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 DiabetesNCT02825251 · 2016-07-06 · 1 site observation
COMPLETED
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced MalignanciesNCT02807844 · 2016-06-29 · 1 site observation
COMPLETED
Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor CancerNCT02713529 · 2016-04-14 · 1 site observation
COMPLETED
IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast CarcinomaNCT02614833 · 2015-12-01 · 1 site observation
COMPLETED
Study of Tremelimumab in Patients With Advanced Solid TumorsNCT02527434 · 2015-11-02 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.